CROI 2017 Program and Information

Program and Agenda

WorkshopW2: CLINICAL TRIAL DESIGN AND ANALYSIS Room 6 C 2:15 PM - 4:00 PM Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies. Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and basic HIV epidemiology. Objectives: At completion of the session, participants will be able to: • Provide examples of different study designs to assess efficacy of new prevention methods in the era of preexposure prophylaxis (PrEP) • Describe approaches to designing and evaluating implementation science trials • Evaluate strengths and limitations of respondent-driven sampling as a method for recruiting and understanding under-studied populations Conveners Susan P. Buchbinder, San Francisco Dept of PH, San Francisco, CA, USA Richard Chaisson, The Johns Hopkins Univ, Baltimore, MD, USA 3 PREVENTION TRIAL DESIGN IN T HE ERA OF PREP Deborah J. Donnell, Fred Hutchinson Cancer Rsr Center, Seattle, WA, USA

Preconference Sessions • Monday 4 IMPLEMENTATION SCIENCE TRIALS: DO THE RULES OF RCTS APPLY? James R. Hargreaves, London Sch of Hygiene and Trop Med, London, United Kingdom 5 RESPONDENT DRIVEN SAMPLING&OTHER METHODS FOR RECRUITING HARD TO REACH POPULATIONS Carl A. Latkin, The Johns Hopkins Univ, Baltimore, MD, USA

WorkshopW3: FRONTIERS IN LABORATORY SCIENCE Room 611-614 2:15 PM - 4:00 PM Target Audience: This session is directed to students, researchers and clinicians who are interested in learning about the application of hot new technologies aimed at profiling the immune response to infection and the intracellular molecular mechanisms exploited by HIV during cellular infection. Level of Knowledge: It is assumed that the participants are familiar with basic immunology and virology. Objectives: • Describe how the CRISPR/Cas9 systemmay be exploited to explore the molecular mechanisms underlying HIV infection • Describe the role of RNA structure in HIV infection and latency • Describe how high-dimensional time-of-flight mass spectrometry may be used to explore single cell immune profile dynamics during infection Conveners Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA Frank Kirchhoff, Ulm Univ Medical Center, Ulm, Germany 6 HIGH-THROUGHPUT GENOME ENGINEERING IN PRIMARY CD4+T CELLS Judd F. Hultquist, Univ of California San Francisco, San Francisco, CA, USA

CROI 2017 30